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• Barriers exist within primary care that prevent 
appropriate treatment for substance abuse disorder:
– Lack of institutional support for prescribing 
buprenorphine due to insufficient staff training, 
lack of time and complex regulations1
– Lack of psychosocial and mental health support2
– Social stigma present within primary care 
heavily represented though language, patient 
identification and treatment3
• Goals:
– Develop  a questionnaire that aims to identify 
stigmatizing language towards individuals with 
opioid use disorder across the interdisciplinary 
teams to target training and education
– Conduct a pilot questionnaire to gather feedback 
and improve the design to fully execute a larger 
scale project with IRB approval in the near future 




Developing a questionnaire and data analysis process: Identification of practice and provider stigma 
score in order to improve and measure training efforts.
Jessica Deemer, Angela Colistra, PhD
Department of Family Medicine 
• Total of 12 articles found including 3 
cohort studies and 2 meta analyses 
• Attended 8 meetings with the PacMAT
team 
• Developed three surveys including three 
patients with moderate opioid use disorder 
but varying socioeconomic backgrounds 
and 9 follow up questions
• Questionnaire reviewed by the Stakeholder 
Groups on the Task Force Team to collect 
feedback on how to improve the 
questionnaire




Phase 1 Review 
Phase 2 Review: 
Pilot 
• Questionnaires developed  and reviewed 
with PacMAT Team 
Frequent Feedback Received 
Remove at least one question 
Replace 'suboxones' with 'buprenorphine’ in question 8
Question 8 should have the option to choose more than one answer 
It is difficult to word a description of the patient and their urine test results to the 
medical assistant as that is always done verbally and briefly
Original Questionnaire Changes Made
“The patient took a urine drug screen and 
the results indicated that she has recently 
used fentanyl and marijuana. How would 
you describe these drug test results to the 
medical assistant?”
“The patient took a urine drug screen and 
the results indicated that she has recently 
used fentanyl and marijuana. How would 
you describe these drug test results to the 
patient”
“What are your beliefs about this patient 
and her response to the urine drug screen? 
”
Question REMOVED
“It is decided to induce the patient on 
suboxones and at her 60 day visit the 
patient takes another urine test. The results 
indicate that she has had a return to 
substance use and there is no 
buprenorphine metabolites in the urine, but 
opioids are in the urine. What would your 
approach be now for the patient?”
- Discontinue buprenorphine and refer to 
higher level of care
- Mandate behavioral health care if 
treatment will continue
-Ask patient about urine drug screen 
results and recovery goals and move 
forward from that place
“It is decided to induce the patient on
buprenorphine and at her 60 day visit the 
patient takes another urine test. The results 
indicate that she has had a return to 
substance use and there is no 
buprenorphine metabolites in the urine, but 
opioids are in the urine. What would your 
approach be now for the patient? You may 
choose more than one answer”
- Discontinue buprenorphine and refer to 
higher level of care
- Mandate behavioral health care if 
treatment will continue
-Ask patient about urine drug screen 
results and recovery goals and move 
forward from that place
-Other, please explain 
• 17 responses were recorded which provided feedback 
Figure 1 displays the most received feedback from participants during the pilot 
Average time taken to complete the 
questionnaire: 7 minutes 
Figure 2 displays the changes made to the questionnaire using the feedback
• Using the feedback from the 17 responses,  changes 
were made to the questionnaire to improve the design 
• In total, 2 open ended questions were removed to 
shorten the length of the survey
• Participants can now choose more than one answer in 
the multiple choice question to ensure the participant 
can fully express their desired treatment plan 
• With changes made, it is estimated for the 
questionnaire to now take an average of five minutes. 
Each questionnaire now includes one patient case, 4 
open ended questions, 1 multiple choice question, and 
2 questions on a Likert scale
• Validate a stigma questionnaire and data tracking 
system using the  addictionary as a  coding tool in order 
to track stigmatizing language4
• Submission of an IRB in order to send the questionnaire 
out on a greater scale
• Send questionnaire to each of the 14 primary care sites
• Collect an average stigma score at each of the 14 
primary care practices 
• Target the primary stigma at each practice and develop 
changes in order to diminish the stigma against opioid 
use disorder patients at each of the practices 
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